WALTHAM, Mass.–(BUSINESS WIRE)–Viridian Therapeutics, Inc. (NASDAQ: VRDN), a biotechnology company focused on discovering, developing and commercializing potentially best-in-class medicines for serious and rare diseases, today announced it entered in…
Stoke Therapeutics Presents Two-Year Natural History Data from Patients with Autosomal Dominant Optic Atrophy (ADOA)
BEDFORD, Mass.–(BUSINESS WIRE)–Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to restoring protein expression by harnessing the body’s potential with RNA medicines, today announced the presentation of two-year data from th…
STAAR Surgical Announces Preliminary Net Sales Results for Third Quarter 2025
LAKE FOREST, Calif.–(BUSINESS WIRE)–STAAR Surgical Company (NASDAQ: STAA), the global leader in phakic IOLs with the EVO family of Implantable Collamer® Lenses (EVO ICL™) for vision correction, today announced preliminary net sales results for the th…
Glaukos Announces FDA Approval of Epioxa™
ALISO VIEJO, Calif.–(BUSINESS WIRE)–Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases, announced today the U…
AURN001 improves visual acuity at 12 months in phase 1/2 trial
ORLANDO — At 12 months, AURN001, an allogenic cell therapy for the treatment of corneal edema secondary to corneal endothelial dysfunction, achieved all primary and secondary endpoints in the phase 1/2 CLARA trial, according to a presenter.“The excitin…
Monitor for ocular complications with antibody-drug conjugates
ORLANDO — Drugs commonly used in cancer immunotherapy carry the risk for ocular adverse events, according to a speaker.In a presentation at Cornea Subspecialty Day at the American Academy of Ophthalmology meeting, Meghan Berkenstock, MD, of Wilmer Eye …